Lrp4 is a receptor for Agrin and forms a complex with MuSK.

Lrp4 is a receptor for Agrin and forms a complex with MuSK.

Neuromuscular synapse formation requires a complex exchange of signals between motor neurons and skeletal muscle fibers, leading to the accumulation of postsynaptic proteins, including acetylcholine receptors in the muscle membrane and specialized release sites, or active zones in the presynaptic ne...

Bibliografske podrobnosti
Main Authors:	Kim, N, Stiegler, A, Cameron, T, Hallock, P, Gomez, A, Huang, J, Hubbard, SR, Dustin, M, Burden, S
Format:	Journal article
Jezik:	English
Izdano:	2008

Podobne knjige/članki

A mutation causes MuSK reduced sensitivity to agrin and congenital myasthenia.
od: Asma Ben Ammar, et al.
Izdano: (2013-01-01)

Correction: A Mutation Causes MuSK Reduced Sensitivity to Agrin and Congenital Myasthenia
Izdano: (2013-01-01)

Correction: A Mutation Causes MuSK Reduced Sensitivity to Agrin and Congenital Myasthenia.
od: Asma Ben Ammar, et al.
Izdano: (2013-01-01)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters
od: Koneczny, I, et al.
Izdano: (2013)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
od: Koneczny, I, et al.
Izdano: (2013)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
od: Inga Koneczny, et al.
Izdano: (2013-01-01)

Agrin Influences Botulinum Neurotoxin A-Induced Nerve Sprouting via miR-144-agrin-MuSK Signaling
od: Lin Ma, et al.
Izdano: (2020-01-01)

The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.
od: Koneczny, I, et al.
Izdano: (2014)

The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis
od: Koneczny, I, et al.
Izdano: (2014)

Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.
od: Leite, M, et al.
Izdano: (2005)

Myasthenia gravis with MuSK antibodies
od: Farrugia, M, et al.
Izdano: (2005)

Potential mechanisms in MuSK-myasthenia gravis
od: Koneczny, I
Izdano: (2014)

MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine
od: Shalini Bhaskar, et al.
Izdano: (2022-01-01)

Synapse-specific Lrp4 mRNA enrichment requires Lrp4/MuSK signaling, muscle activity and Wnt non-canonical pathway
od: Hongyang Jing, et al.
Izdano: (2021-06-01)

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models
od: Jamie L. Lim, et al.
Izdano: (2025-02-01)

Increasing MuSK Activity Delays Denervation and Improves Motor Function in ALS Mice
od: María J. Pérez-García, et al.
Izdano: (2012-09-01)

Infantile Onset Myasthenia Gravis with MuSK Antibodies
od: J Gordon Millichap
Izdano: (2006-08-01)

Studies of the MuSK system using molecular dynamics simulations
od: Buyan, A
Izdano: (2015)

The prevalence of MuSK antibody positive myasthenia gravis worldwide
od: Vincent, A, et al.
Izdano: (2006)

Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody
od: Sarah Cantor, et al.
Izdano: (2018-02-01)

Clinical aspects of MuSK antibody positive seronegative MG.
od: Sanders, D, et al.
Izdano: (2003)

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.
od: McConville, J, et al.
Izdano: (2004)

MuSK antibody-positive, seronegative myasthenia gravis in Korea.
od: Lee, J, et al.
Izdano: (2006)

Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
od: Shiraishi, H, et al.
Izdano: (2005)

MuSK Antibody Positive Myasthenia Gravis Mimicking as Myositis
od: Nilesh Wagh, et al.
Izdano: (2024-09-01)

MuSK-Associated Myasthenia Gravis: Clinical Features and Management
od: Carmelo Rodolico, et al.
Izdano: (2020-07-01)

Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.
od: Farrugia, M, et al.
Izdano: (2007)

Dok-7/MuSK signaling and a congenital myasthenic syndrome.
od: Yamanashi, Y, et al.
Izdano: (2008)

Anti-MuSK antibodies in a case of ocular myasthenia gravis.
od: Bennett, D, et al.
Izdano: (2006)

Anti-MuSK antibody positive myasthenia gravis with childhood onset
od: Diana Epure, et al.
Izdano: (2016-06-01)

Progress in rituximab for anti⁃MuSK antibody-related myasthenia gravis
od: Ting LI, et al.
Izdano: (2020-01-01)

Clinical Characteristics of MuSK Antibody-positive Myasthenia Gravis in Taiwan
od: Yung-Chuan Huang, et al.
Izdano: (2008-07-01)

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
od: Hoch, W, et al.
Izdano: (2001)

Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.
od: Phillips, W, et al.
Izdano: (2015)

MuSK-antibody-positive myasthenia gravis in a South Asian population.
od: Chang, T, et al.
Izdano: (2009)

Anti-MuSK antibodies in seronegative myasthenia gravis: a cause of denervation
od: Newsom-Davis, J, et al.
Izdano: (2001)

Targeted treatment approaches and pathogenicity of antibody subclasses in MuSK-myasthenia gravis
od: Cao, M
Izdano: (2021)

Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation
od: Fangyi Shi, et al.
Izdano: (2024-11-01)

Coexistence of anti-MuSK antibody-positive myasthenia gravis and rheumatoid arthritis
od: Amber Eker, et al.
Izdano: (2020-08-01)

Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China
od: Zunwei Zhang, et al.
Izdano: (2020-10-01)